Australia markets closed

Vaccinex, Inc. (VCNX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.8100-0.0200 (-1.09%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.8300
Open1.8100
Bid0.0000 x 900
Ask0.0000 x 900
Day's range1.8000 - 1.8700
52-week range1.6400 - 9.5600
Volume58,898
Avg. volume95,432
Market cap56.366M
Beta (5Y monthly)1.73
PE ratio (TTM)N/A
EPS (TTM)-1.1530
Earnings date11 Nov 2021 - 15 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.00
  • GlobeNewswire

    Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit

    ROCHESTER, N.Y., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, a potent biological mediator, today announced that Elizabeth Evans, PhD, Chief Operating Officer, is scheduled to present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit. Vaccinex’s SIGNAL-AD trial, a Phase 1/2 trial of pepinem

  • GlobeNewswire

    Vaccinex CEO, Dr. Maurice Zauderer, Presented New and Promising Phase 2 SIGNAL Trial Data in a Plenary Session at the European Huntington’s Disease Network Meeting

    ROCHESTER, N.Y., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, a potent biological mediator, today announced that Maurice Zauderer, PhD, Chief Executive Officer, presented new and promising data from continued analysis of final results of the phase 2 SIGNAL Huntington’s Disease Trial at the European Huntington Disease N

  • GlobeNewswire

    Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update

    Patients are currently being screened and enrolled in two studies of pepinemab as monotherapy in Alzheimer’s disease and in combination with KEYTRUDA® in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Ended the second quarter with cash and cash equivalents of $22.4 million ROCHESTER, N.Y., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through t